Equillium (EQ) Announces Katherine Xu, Ph.D. to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 9, 2021 8:00 AM ESTLA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equilliums board of directors, effective Thursday, February 4, 2021.
Were excited to have Dr. Xu join the board of directors, as she brings with her a wealth of both scientific and Wall Street acumen, said Dan Bradbury, executive chairman of the board of directors at Equillium. Her addition complements the skills... More
